1250P Camrelizumab plus apatinib combined with POF in patients with untreated advanced gastric cancer (UAGC): A single-center, open-label, single-arm, phase II trial (SYLT-017)
作者
L. Su,S. Zhao,P. Lin,Y. Yin,R. Lin
出处
期刊:Annals of Oncology [Elsevier BV] 日期:2022-09-01卷期号:33: S1119-S1120被引量:11